Codexis, Inc. (CDXS)
Designs enzymes that make pharmaceutical manufacturing faster and cheaper.
$1.50-0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-44.2%
The outlook
CDXS is trading near the bottom of its 52-week range and below both its 50- and 200-day moving averages, signaling weak near-term momentum. Analyst coverage leans bullish with an average price target about 339% above current levels, though the overall market sentiment scores bearish. The disconnect between analyst targets and current price reflects significant uncertainty about the stock's near-term direction.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range19% of the way from its 52-week low to high
Price targetAvg target +339% vs current price
Analyst price target
~12-month · 6 analysts$6.58average target+338.9% vs now
Now $1.50
Low $2.00High $11.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$136.3M
52-wk high
$3.87
52-wk low
$0.96
50-day avg
$2.41
200-day avg
$2.00
Trailing P/E
—